Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose human albumin to prevent paracentesis-induced circulatory dysfunction in cirrhotic patients with acute decompensation or ACLF (<5 L paracentesis)
TCTR20231120001Phase 3Unknown
- Sponsor
- Faculty of Medicine, Prince of Songkhla University
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of albumin (human) in Cirrhosis, acute-on-chronic liver failure (ACLF), ascites, sponsored by Faculty of Medicine, Prince of Songkhla University. Status: unknown.
02
Drugs
albumin (human)
03
Conditions
Cirrhosisacute-on-chronic liver failure (ACLF)ascites
Beyond the preview
Go deeper on TCTR20231120001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20231120001.